Most common questions asked about Esbriet
Esbriet is an anti-fibrotic and anti-inflammatory drug used in the treatment of mild to moderate IPF. It is manufactured by Genentech and was approved by the FDA in 2014. This drug can help reduce the amount of lung fibrosis by blocking secretions responsible for excessive collagen production, along with reducing inflammation in the lungs.
Even though it has been approved a few years ago, there are still a lot of doubts around it.
Check “7 Common Questions About Esbriet” here to learn more about it.
Do you have any other questions about it? Share your doubts below and maybe some other forums member can help answer your questions!
Log in to reply.